Lab21 gains Ark heart attack diagnostics licence:
This article was originally published in Clinica
Executive Summary
Hampshire, UK-based diagnostics group Lab21 has gained exclusive UK and international rights to market Ark Therapeutics' oxidised low-density lipoprotein (Ox-LDL) auto-antibody diagnostic test kit. The Ox-LDL test is a CE-marked heart attack risk assessment system and will be further trialled by Lab21 until it is ready for launch. Thereafter, Lab21 will conduct all sales and marketing activities for the product. Ark (London, UK) will receive a mix of up-front and milestone payments, together with a 5% royalty on future sales of the test. Both companies are targeting the cardiovascular disease market - according to Ark, one in five males and one in six females in the UK die of cardiovascular disease.